EUVIMEDEUVIMED entdecken
Crossref

PD02.05. Long-Term Incidence and Treatment Outcomes of Gastric Conduit Cancer After Esophagectomy

Hyun Ki Jeong, Sung Yong Park, Tae Se Kim, Yang Won Min, Dong Ryul Oh, Seh Hoon Park, Jong Mu Sun, Yeong Jeong Jeon, Jung Hee Lee, Jong Ho Cho, Hong Kwan Kim, Yong Soo Choi

Diseases of the Esophagus · 22.08.2026 · 39 (Supplement_1)

DOI: 10.1093/dote/doag077.083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diseases of the Esophagus, online erschienen am 22.08.2026. Verfasst von Hyun Ki Jeong und 11 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Topic Esophageal Cancer: Other Background Gastric conduit cancer (GCC), a primary carcinoma arising in the reconstructed gastric conduit after esophagectomy, is rare, and its true incidence and long-term outcomes remain unclear. We aimed to determine its cumulative incidence and treatment-related outcomes.

Methods

We retrospectively reviewed 4,490 patients who underwent esophagectomy with gastric conduit reconstruction between 1994 and August 2025. Among them, 93 developed GCC during follow-up. Clinical characteristics and treatment outcomes of these patients were analyzed.

Results

The cumulative incidence of GCC was 2.22% at 10 years and 3.16% at 20 years, with a median interval of 48.2 months (IQR, 26.0–94.1) from esophagectomy to diagnosis. All tumors were adenocarcinomas. Surgical resection was performed in 14 patients (take-down of gastric conduit and colon interposition, n=11; partial gastrectomy or wedge resection, n=3) without postoperative mortality, with a median event-free survival (EFS) of 107.9 months and a 5-year EFS of 77.9%. Endoscopic therapy was the most common treatment (n=64; endoscopic submucosal dissection (ESD), n=62; argon plasma coagulation, n=2), with a median EFS of 56.4 months and a 5-year EFS of 48.2%; two patients required salvage surgery, and seven experienced recurrence at a median of 30.9 months. Eight patients received radiation therapy / concurrent chemoradiation therapy (median EFS 83.0 months; 5-year EFS 60.0%), and eight underwent chemotherapy or palliative care (median EFS 11.1 months; 5-year EFS 0%).

Conclusion

GCC remains a clinically significant long-term complication after esophagectomy. Endoscopic therapy offers favorable outcomes for early-stage disease, whereas advanced-stage GCC carries a poor prognosis. Therefore, structured and lifelong endoscopic surveillance is crucial for early detection and for improving long-term survival after esophagectomy.

Zitieren

APA

Jeong, H. K., Park, S. Y., Kim, T. S., Min, Y. W., Oh, D. R., Park, S. H., Sun, J. M., Jeon, Y. J., Lee, J. H., Cho, J. H., Kim, H. K., & Choi, Y. S. (2026). PD02.05. Long-Term Incidence and Treatment Outcomes of Gastric Conduit Cancer After Esophagectomy. Diseases of the Esophagus, 39(Supplement_1). https://doi.org/10.1093/dote/doag077.083

Vancouver

Jeong HK, Park SY, Kim TS, Min YW, Oh DR, Park SH, et al. PD02.05. Long-Term Incidence and Treatment Outcomes of Gastric Conduit Cancer After Esophagectomy. Diseases of the Esophagus. 2026;39(Supplement_1). doi:10.1093/dote/doag077.083

BibTeX
@article{Jeong2026,
  author = {Jeong, Hyun Ki and Park, Sung Yong and Kim, Tae Se and Min, Yang Won and Oh, Dong Ryul and Park, Seh Hoon and Sun, Jong Mu and Jeon, Yeong Jeong and Lee, Jung Hee and Cho, Jong Ho and Kim, Hong Kwan and Choi, Yong Soo},
  title = {PD02.05. Long-Term Incidence and Treatment Outcomes of Gastric Conduit Cancer After Esophagectomy},
  journal = {Diseases of the Esophagus},
  year = {2026},
  volume = {39},
  number = {Supplement_1},
  doi = {10.1093/dote/doag077.083}
}
Kostenlos starten →